Veradermics Inc
Research Veradermics Inc (MANE) on Bullrun: market cap USD 4.28B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMANE
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.28B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 27.23M
- Free cash flow-USD 21.17M
Valuation Snapshot
latest market cap is USD 4.28B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -USD 70.00M | -USD 71.63M | n/a | -111.91 | USD 21.77M | USD 4.00K | -USD 121.01M |
| FY2024 | n/a | -USD 26.49M | -USD 23.69M | n/a | -37.05 | USD 53.08M | USD 0 | -USD 48.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.28B | n/a | n/a | n/a |
About Veradermics Inc
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Veradermics Inc's market cap?
Veradermics Inc's market capitalization is USD 4.28B.
What does Veradermics Inc do?
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum.